280 related articles for article (PubMed ID: 28293857)
21. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.
Okuda Y; Mizutani M; Ikegami T; Ueno E; Yamashita K
Arzneimittelforschung; 1992 Apr; 42(4):540-2. PubMed ID: 1642679
[TBL] [Abstract][Full Text] [Related]
22. Retinopathy, nephropathy, peripheral neuropathy and geriatric scale scores in elderly people with Type 2 diabetes.
Le Floch JP; Doucet J; Bauduceau B; Verny C;
Diabet Med; 2014 Jan; 31(1):107-11. PubMed ID: 24111927
[TBL] [Abstract][Full Text] [Related]
23. Cilostazol in the management of vascular disease.
Dalainas I
Int Angiol; 2007 Mar; 26(1):1-7. PubMed ID: 17353881
[TBL] [Abstract][Full Text] [Related]
24. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease.
O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
Angiology; 2008 Dec-2009 Jan; 59(6):695-704. PubMed ID: 18796444
[TBL] [Abstract][Full Text] [Related]
25. Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
Liu JS; Chuang TJ; Chen JH; Lee CH; Hsieh CH; Lin TK; Hsiao FC; Hung YJ
Endocrine; 2015 Aug; 49(3):703-10. PubMed ID: 25666934
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic potential of VEGF inhibition in diabetic microvascular complications.
Tremolada G; Lattanzio R; Mazzolari G; Zerbini G
Am J Cardiovasc Drugs; 2007; 7(6):393-8. PubMed ID: 18076206
[TBL] [Abstract][Full Text] [Related]
27. How to prevent the microvascular complications of type 2 diabetes beyond glucose control.
Valencia WM; Florez H
BMJ; 2017 Jan; 356():i6505. PubMed ID: 28096078
[TBL] [Abstract][Full Text] [Related]
28. Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients.
Jensen T; Deckert T
Horm Metab Res Suppl; 1992; 26():68-70. PubMed ID: 1490695
[TBL] [Abstract][Full Text] [Related]
29. Cilostazol treatment of claudication in diabetic patients.
Rendell M; Cariski AT; Hittel N; Zhang P
Curr Med Res Opin; 2002; 18(8):479-87. PubMed ID: 12564659
[TBL] [Abstract][Full Text] [Related]
30. Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
Jiao XM; Jiao XJ; Zhang XG; Xu XP; Wu JX; Yao L; Zhao J; Lü XF
Chin Med J (Engl); 2013 Nov; 126(22):4395-6. PubMed ID: 24238537
[No Abstract] [Full Text] [Related]
31. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
[TBL] [Abstract][Full Text] [Related]
32. [Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].
You LZ; Lin YX; Fang ZH; Shen GM; Zhao JD; Wang TT
Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4700-4706. PubMed ID: 29493134
[TBL] [Abstract][Full Text] [Related]
33. Orthostatic hypotension in diabetic patients-10-year follow-up study.
Gaspar L; Kruzliak P; Komornikova A; Celecova Z; Krahulec B; Balaz D; Sabaka P; Caprnda M; Kucera M; Rodrigo L; Uehara Y; Dukat A
J Diabetes Complications; 2016; 30(1):67-71. PubMed ID: 26412028
[TBL] [Abstract][Full Text] [Related]
34. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.
Suzuki K; Uchida K; Nakanishi N; Hattori Y
Am J Hypertens; 2008 Apr; 21(4):451-7. PubMed ID: 18369362
[TBL] [Abstract][Full Text] [Related]
35. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Tang WH; Lin FH; Lee CH; Kuo FC; Hsieh CH; Hsiao FC; Hung YJ
Endocrine; 2014 Mar; 45(2):293-301. PubMed ID: 23775007
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of inflammatory and vascular endothelial dysfunction biomarkers in microvascular and macrovascular complications in type 1 diabetes.
Wołoszyn-Durkiewicz A; Myśliwiec M
Pediatr Endocrinol Diabetes Metab; 2019; 25(1):28-35. PubMed ID: 31343130
[TBL] [Abstract][Full Text] [Related]
37. Prevention of microvascular and macrovascular complications in diabetes mellitus.
Maji D
J Indian Med Assoc; 2004 Aug; 102(8):426, 428, 430 passim. PubMed ID: 15719805
[TBL] [Abstract][Full Text] [Related]
38. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome.
Abdul-Ghani M; Nawaf G; Nawaf F; Itzhak B; Minuchin O; Vardi P
Isr Med Assoc J; 2006 Jun; 8(6):378-82. PubMed ID: 16833164
[TBL] [Abstract][Full Text] [Related]
39. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
40. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus.
Gabat S; Keller C; Kempe HP; Amiral J; Ziegler R; Ritz E; Bergis KH; Wahl P; Nawroth P
Vasa; 1996; 25(3):233-41. PubMed ID: 8795304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
